CYP2E1: from ASH to NASH

被引:103
作者
Lieber, CS [1 ]
机构
[1] Mt Sinai Sch Med, Bronx VA Med Ctr 151 2, Sect Liver Dis & Nutr, Bronx, NY 10468 USA
基金
美国国家卫生研究院;
关键词
alcoholic steatosis; alcoholic steatohepatitis; nonalcoholic steatchepatitis; cytochrome P4502E1; obesity;
D O I
10.1016/j.hepres.2003.08.001
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The pathology of the liver in alcoholic steatosis and alcoholic steatohepatitis (ASH) is remarkably similar to that of nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH), suggesting some common pathogenic mechanism. Studies carried out over the last three decades of possible mechanisms involved revealed one common link, namely the induction of cytochrome P4502E1 Its substrates include fatty acids, ketones and ethanol. These substances, when present chronically in large amounts, induce the activity of the enzyme which thereby contributes to the disposition of these substrates. This reaction, however, is associated with the release of free radicals which can cause lipid peroxidation and liver injury, including mitochondrial damage. Mitochondrial damage in turn exacerbates the oxidative stress. CYP2E1 can also convert various xenobiotics to toxic metabolites. When unchecked, this toxicity eventually results in inflammation and fibrosis, culminating in cirrhosis. Prevention of this disorder is based on limiting the substrates that induce the system, such as excessive fatty acid associated with obesity and excessive alcohol consumption. No effective pharmacologic treatment is presently available but there is ongoing research on possible inhibitors of CYP2E1, innocuous enough to be suitable for chronic human consumption and sufficiently effective to attenuate the CYP2E1 induction to avoid the consequences of its excessive activity while maintaining its physiologic role. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 139 条
[61]   CONTRIBUTION OF CYTOCHROME P450S TO MEOS (MICROSOMAL ETHANOL-OXIDIZING SYSTEM) - A SPECIFIC AND SENSITIVE ASSAY OF MEOS ACTIVITY BY HPLC WITH FLUORESCENCE LABELING [J].
KUNITOH, S ;
TANAKA, T ;
IMAOKA, S ;
FUNAE, Y ;
MONNA, Y .
ALCOHOL AND ALCOHOLISM, 1993, 28 :63-68
[62]  
LAETHEM RM, 1993, J BIOL CHEM, V268, P12912
[63]  
LANE BP, 1966, AM J PATHOL, V49, P593
[64]  
LANE BP, 1967, LAB INVEST, V16, P342
[65]   PURIFICATION AND CHARACTERIZATION OF HUMAN-LIVER CYTOCHROME-P-450-ALC [J].
LASKER, JM ;
RAUCY, J ;
KUBOTA, S ;
BLOSWICK, BP ;
BLACK, M ;
LIEBER, CS .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1987, 148 (01) :232-238
[66]  
LEE RG, 1999, TXB CLIN HEPATOLOGY, P1251
[67]  
LIEBER CS, 1970, J BIOL CHEM, V245, P2505
[68]   EFFECT OF ETHANOL ON FATTY ACID METABOLISM - STIMULATION OF HEPATIC FATTY ACID SYNTHESIS IN VITRO [J].
LIEBER, CS ;
SCHMID, R .
JOURNAL OF CLINICAL INVESTIGATION, 1961, 40 (02) :394-&
[69]  
Lieber CS, 1999, ALCOHOL CLIN EXP RES, V23, P991, DOI 10.1111/j.1530-0277.1999.tb04217.x
[70]   Hepatic and other medical disorders of alcoholism: From pathogenesis to treatment [J].
Lieber, CS .
JOURNAL OF STUDIES ON ALCOHOL, 1998, 59 (01) :9-25